Drug Profile
Influenza virus vaccine quadrivalent - Protein Sciences Corporation
Alternative Names: FluBlok Quadrivalent; FluBlok-Q; PSC Flu vaccine (4 strains); Quadrivalent recombinant influenza vaccine seasonal – Protein Sciences Corporation; RIV4; Seasonal quadrivalent influenza vaccine – Protein Sciences Corporation; Supemtek (quadrivalent recombinant influenza vaccine)Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Protein Sciences Corporation
- Developer Laboratorios Liomont; Protein Sciences Corporation; Sanofi
- Class Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 10 Jan 2024 Sanofi Pasteur terminates phase III trial in in Influenza virus infections (In children, Prevention) in Spain (IM) (NCT05513391, EudraCT2022-000576-19)
- 29 Sep 2022 Phase-III clinical trials in Influenza virus infections (In adults, Prevention) in Singapore (IM) (NCT05479370)
- 29 Jul 2022 Phase-III clinical trials in Influenza virus infections (In children, Prevention) in Spain (IM) (EudraCT2022-000576-19)